Heterologous prime-boost vaccination strategies for HIV-1: Augmenting cellular immune responses

Current Opinion in Investigational Drugs

Volumn 3, Issue 3, 2002, Pages 374-378

  Newman, Mark J ^a  

^a Epimmune   (United States)

Author keywords

DNA vaccines; Heterologous prime boost; HIV; T lymphocyte; Viral vaccine vectors

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT GLYCOPROTEIN GP 120; RECOMBINANT PROTEIN; VIRUS DNA; VIRUS VECTOR;

CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EXPERIMENTAL MODEL; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PRIMATE; REVIEW; VACCINATION;

AIDS VACCINES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; VACCINATION;

EID: 0036229959     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
2. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
3. CD8+ cells in human immunodeficiency virus type I pathogenesis: Cytolytic and noncytolytic inhibition of viral replication
4. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
5. The role of cytotoxic T-cells in HIV infection
6. Role of cellular immunity in protection against HIV infection
7. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
8. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection
9. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
10. + lymphocyte activity
11. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor
12. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
13. Long-term non-progression in HIV infection: Clinico pathological issues
14. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
15. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
16. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
17. The role of CD4+ T helper cells in the cytotoxic T lymphocyte response to HIV-1
18. HIV-1-specific CD4+ cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
19. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1
20. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant
21. Factors contributing to the lack of human immunodeficiency virus type 1 (HIV-1) transmission in HIV-1-discordant partners
22. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
23. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors
24. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi
25. Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53
26. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre- existing HIV-specific CD8+ responses
27. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection
28. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
29. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes
30. Control of HIV despite the discontinuation of antiretroviral therapy
31. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
32. Immune control of HIV-1 after early treatment of acute infection
33. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
34. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy
35. Anti-HIV cellular immunity: Recent advances towards vaccine design
36. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
37. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: Analysis of the durability of responses and effect of repeated boosting
38. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus
39. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type I (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160
40. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiecy virus type 1 envelope with a combination vaccine regimen
41. SF2 recombinant gp120, or both vaccines in seronegative adults
42. + cytotoxic T lymphocyte responses in seronegative volunteers
43. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group
44. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: A phase 2 study in higher-and lower-risk volunteers
45. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime MVA boost vaccination regime
46. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
47. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime
48. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
49. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
50. Development of adjuvant-active nonionic block copolymers
51. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity
52. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules
53. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS
54. Design and construction of an experimental HIV-1 vaccine for a year- 2000 clinical trial in Kenya
55. Immunogenicities of intravenous and intramuscular administrations of modified vaccine virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice
56. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily - Implications for vaccine development
57. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif
58. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes
59. Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency-virus immunity